AZN Stock Chart & Fundamental Analysis

Interactive Chart

About AstraZeneca PLC

Name

AstraZeneca PLC

CEO

Pascal Claude Roland Soriot

Website

www.astrazeneca.com

Industry

Healthcare

Year Founded

1999

Employees

94,300

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and supplies medicines used in hospitals and clinics around the world. The operating idea is steady and practical: move research through development, manufacture to consistent standards, and support appropriate use with clear guidance for clinicians. Programs focus on conditions that require long-term treatment and careful monitoring, so labeling, education, and supply planning sit close to scientific work. Country teams adapt access and information to local frameworks while holding to common safety principles. The purpose is to turn complex science into options that fit daily care, with availability that health systems can plan around rather than chase.

Analyst Ratings

Consensus Recommendation

Buy16

Hold4

Sell3

Fundamentals & Financials

Revenue (TTM)

$58.7B

Net Income (TTM)

$10.2B

EPS (TTM)

$13.2

ROA (TTM)

9.09%

Current Ratio

0.94

Dividend Yield

0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q4 2025	Q3 2025	Q2 2025
Revenue	$15,503M	$15,191M	$14,457M
Cost of Sales	$3,118M	$2,801M	$2,473M
Gross Profit	$12,385M	$12,390M	$11,984M
Operating Income	$2,978M	$3,583M	$3,508M
Net Income	$2,326M	$2,533M	$2,450M
EPS	$3.02	$3.26	$3.16

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

AstraZeneca PLC's Technical Indicators Summary

AstraZeneca shows a bullish technical profile driven by constructive momentum and broad moving-average support. The stock sits above its short- and medium-term averages and well clear of the 200‑day level, while CCI and MACD readings point to positive momentum and RSI sits in a firm but not overbought range. Volume-based OBV is supportive and the classic pivot near 200.40 sits just below the current price, while volatility is moderate. Technical takeaway: overall bullish bias with momentum and moving-average confirmation, though the upper Bollinger band is near current trade.

Buy

16 signals

Neutral

4 signals

Sell

3 signals

Overall: Bullish70% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	63.90	Neutral	RSI (63.90) is neutral.
Stochastic %K (14, 3, 3)	96.86	Sell	Stochastic (96.86) > 80, indicating overbought.
CCI (20)	185.43	Buy	CCI (185.43) > 100, indicating strong upward momentum.
WPR (14)	-3.87	Sell	Williams %R (-3.87) > -20, indicating overbought.
Momentum (10)	14.56	Buy	Momentum (14.56) is positive.
MFI	63.11	Neutral	MFI (63.11) is neutral.
MACD Level (12, 26)	0.25	Buy	Confirmed uptrend: MACD (0.25) is positive and above its signal line (-1.50).
Bollinger Bands	$180.49 - $202.33	Sell	Price ($203.49) is above the upper band ($202.33).
ATR (14)	$4.60 (2.26%)	Neutral	Moderate Volatility (2.26%).
ADX (14)	22.96	Neutral	Weak or consolidating trend (ADX < 25). ADX(22.96), +DI(33.83), -DI(24.02)
OBV	73,134,000	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(73,134,000), 20D-SMA-OBV(62,947,475)
Classic Pivot Point	$200.40	Buy	Price ($203.49) has broken above resistance R1 ($202.07) — bullish breakout potential.
Fibonacci Pivot Point	$200.40	Buy	Price ($203.49) has broken above resistance R1 ($201.55) — bullish breakout potential.
Simple Moving Averages	$171.71 - $194.72(5 indicators)	Buy	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$172.47 - $194.33(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the close, AZN held onto a small 1.37% gain versus yesterday, finishing at 203.49. By the final tick, AZN's options tape still flagged intense hedging, with PCR at 1.83. AZN ticks higher on Syneron Bio's Series B financing, in which AZN remains a shareholder.

Price Change

from $203.47 close

-$0.04

Trading Volume

Below avg (2.1M)

1.9M

vs S&P 500 Today

Outperforming Market

+2.65%

52-Week Position

Upper range

89.8%